Of these, around 20,000 had been prescribed glucagon-like peptide-1 (GLP-1) receptor agonists
These compounds reduce central neuroinflammation by lowering interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha (TNF-), and limiting oxidative stress ( On the other side, current trends in precision psychiatry aim to classify subpopulations of patients with inflammatory depression, characterized by elevated markers of inflammation, increased glucose and lipid levels, neurovegetative symptoms, anxiety or irritability, and suicidal ideation (Wessa et al., 2026)
Compounding pharmacies adhere to strict regulations and quality standards to ensure the safety and efficacy of the customized medications they produce
doi:10.4103/0976-9668.149076
[23] [24] Recent observational studies examining GLP-1 use in patients with IBD have generally not shown a clear increase in IBD exacerbations or flares